358 related articles for article (PubMed ID: 33833111)
1. Recruiting T cells in cancer immunotherapy.
Yost KE; Chang HY; Satpathy AT
Science; 2021 Apr; 372(6538):130-131. PubMed ID: 33833111
[No Abstract] [Full Text] [Related]
2. Releasing the Brakes on Cancer Immunotherapy.
Ribas A
N Engl J Med; 2015 Oct; 373(16):1490-2. PubMed ID: 26348216
[No Abstract] [Full Text] [Related]
3. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
5. [Not Available].
Senant M; Giusti D; Weiss L; Dragon-Durey MA
Bull Cancer; 2016 Nov; 103 Suppl 1():S175-S185. PubMed ID: 28057182
[TBL] [Abstract][Full Text] [Related]
6. Introduction: Cancer Immunology Special Issue-Immunotherapy.
Kawakami Y
Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
[No Abstract] [Full Text] [Related]
7. Cellular immunotherapy of cancer: an overview and future directions.
Tao Z; Li S; Ichim TE; Yang J; Riordan N; Yenugonda V; Babic I; Kesari S
Immunotherapy; 2017 Jun; 9(7):589-606. PubMed ID: 28595516
[TBL] [Abstract][Full Text] [Related]
8. Regulatory T cells in cancer; can they be controlled?
Adeegbe DO; Nishikawa H
Immunotherapy; 2015; 7(8):843-6. PubMed ID: 26316166
[No Abstract] [Full Text] [Related]
9. Human Anti-tumor Immunity: Insights from Immunotherapy Clinical Trials.
Egen JG; Ouyang W; Wu LC
Immunity; 2020 Jan; 52(1):36-54. PubMed ID: 31940272
[TBL] [Abstract][Full Text] [Related]
10. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
Furness AJ; Quezada SA; Peggs KS
Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
[No Abstract] [Full Text] [Related]
11. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
[TBL] [Abstract][Full Text] [Related]
12. Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle.
Yan W; Jiang S
Trends Cancer; 2020 Jun; 6(6):506-517. PubMed ID: 32460004
[TBL] [Abstract][Full Text] [Related]
13. Dendritic Cells, the T-cell-inflamed Tumor Microenvironment, and Immunotherapy Treatment Response.
Garris CS; Luke JJ
Clin Cancer Res; 2020 Aug; 26(15):3901-3907. PubMed ID: 32332013
[TBL] [Abstract][Full Text] [Related]
14. STING signaling: a key to therapeutic tumor immunity.
Foote JB; Emens LA
Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
[No Abstract] [Full Text] [Related]
15. CCL21 Programs Immune Activity in Tumor Microenvironment.
Sharma S; Kadam P; Dubinett S
Adv Exp Med Biol; 2020; 1231():67-78. PubMed ID: 32060847
[TBL] [Abstract][Full Text] [Related]
16. Regulation of PD-1 in T cells for cancer immunotherapy.
Yu X; Gao R; Li Y; Zeng C
Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
[TBL] [Abstract][Full Text] [Related]
17. Common phenotypic dynamics of tumor-infiltrating lymphocytes across different histologies upon checkpoint inhibition: impact on clinical outcome.
Araujo B de Lima V; Borch A; Hansen M; Draghi A; Spanggaard I; Rohrberg K; Reker Hadrup S; Lassen U; Svane IM
Cytotherapy; 2020 Apr; 22(4):204-213. PubMed ID: 32201034
[TBL] [Abstract][Full Text] [Related]
18. Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN-γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy.
Lin X; Zeng T; Lin J; Zhang Q; Cheng H; Fang S; Lin S; Chen Y; Xu Y; Lin J
Cancer Biol Ther; 2020; 21(2):130-138. PubMed ID: 31690181
[TBL] [Abstract][Full Text] [Related]
19. Tissue-resident memory-like T cells in tumor immunity: Clinical implications.
Dhodapkar MV; Dhodapkar KM
Semin Immunol; 2020 Jun; 49():101415. PubMed ID: 33011063
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
Sweis RF; Galsky MD
Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
